Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Avoid Large Crowds In Bali & Swim At This Peaceful Waterfall With A Gorgeous, Natural Pool - 2Kaiser Permanente affiliates to pay $556 million to resolve US claims alleging Medicare fraud
- 312 times rockets and spacecraft crashed and burned in 2025
- 4These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- 5EU foreign ministers commemorate Russian massacre in Bucha
- See tonight’s solar storm unfold across the world
- WHO suspends medical evacuations from Gaza following death of contractor in 'security incident'
- Violence 'never part' of break-in plan, court told
- Quantum Computing’s Next Major Breakthroughs Could Come From Australia
- Figure out How to Use the Experience of a Fender bender Legal counselor for Your Potential benefit
- Figure out How to Score Huge with Open Record Rewards
- Triumph's 400 Range Has Just Changed In India, And Here's Why
- Industrial zone damaged in Negev, falls in Sharon area after Iran fires missiles towards Israel
- Unusual 'ingredients' helped stars form in a galaxy near the Milky Way
